Physician profile
Christopher E Earles
NPI 1750431854
$5,360.75
in general payments reported to CMS, 2019-2025
26 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $590 · 2023: $174 · 2024: $1,903 · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Travel and Lodging: $743 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.42 |
| Travel and Lodging | $742.58 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,337.33 | 2024-2025 | |
| Abbvie INC. | $431.78 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $428.64 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $404.14 | 2022-2024 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $341.16 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $285.10 | 2025 | Airsupra |
| Genzyme Corporation | $278.92 | 2025 | |
| Dexcom, INC. | $275.92 | 2022-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $218.34 | 2022 | |
| Pfizer INC. | $140.01 | 2025 | |
| Janssen Scientific Affairs, LLC | $122.11 | 2021 | |
| Madrigal Pharmaceuticals | $121.13 | 2025 | Rezdiffra |
| Ardelyx, INC. | $120.93 | 2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $109.01 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.76 | 2024 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $108.27 | 2021 | |
| Mallinckrodt Hospital Products INC. | $96.19 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $96.19 | 2025 | Iqirvo |
| Lilly USA, LLC | $94.95 | 2025 | Mounjaro |
| Amgen INC. | $77.87 | 2025 | Repatha |
| Intuitive Surgical, INC. | $50.00 | 2023 | Da Vinci Surgical System |
| Boston Scientific Corporation | $30.88 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $29.03 | 2025 | Zenpep |
| Medtronic, INC. | $20.54 | 2025 | Pillcam |
| Almatica Pharma LLC | $18.69 | 2021 | |
| Celltrion USA INC. | $14.86 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Earles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.